183 related articles for article (PubMed ID: 22579791)
1. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5.
Herr D; Sallmann A; Bekes I; Konrad R; Holzheu I; Kreienberg R; Wulff C
Gynecol Oncol; 2012 Oct; 127(1):210-6. PubMed ID: 22579791
[TBL] [Abstract][Full Text] [Related]
2. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Bekes I; Friedl TW; Köhler T; Möbus V; Janni W; Wöckel A; Wulff C
Mol Cancer; 2016 Feb; 15():13. PubMed ID: 26868378
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
4. Human chorionic gonadotropin controls luteal vascular permeability via vascular endothelial growth factor by down-regulation of a cascade of adhesion proteins.
Herr D; Fraser HM; Konrad R; Holzheu I; Kreienberg R; Wulff C
Fertil Steril; 2013 May; 99(6):1749-58. PubMed ID: 23465821
[TBL] [Abstract][Full Text] [Related]
5. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
8. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
9. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
11. VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Urick ME; Giles JR; Johnson PA
Gynecol Oncol; 2008 Sep; 110(3):418-24. PubMed ID: 18606441
[TBL] [Abstract][Full Text] [Related]
12. Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?
Bekes I; Löb S; Holzheu I; Janni W; Baumann L; Wöckel A; Wulff C
Cancer Sci; 2019 Jun; 110(6):1872-1882. PubMed ID: 30843637
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.
Nagy JA; Masse EM; Herzberg KT; Meyers MS; Yeo KT; Yeo TK; Sioussat TM; Dvorak HF
Cancer Res; 1995 Jan; 55(2):360-8. PubMed ID: 7812969
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Akutagawa N; Nishikawa A; Iwasaki M; Fujimoto T; Teramoto M; Kitajima Y; Endo T; Shibuya M; Kudo R
Jpn J Cancer Res; 2002 Jun; 93(6):644-51. PubMed ID: 12079512
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
17. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Jeon BH; Jang C; Han J; Kataru RP; Piao L; Jung K; Cha HJ; Schwendener RA; Jang KY; Kim KS; Alitalo K; Koh GY
Cancer Res; 2008 Feb; 68(4):1100-9. PubMed ID: 18281485
[TBL] [Abstract][Full Text] [Related]
18. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.
Luo JC; Yamaguchi S; Shinkai A; Shitara K; Shibuya M
Cancer Res; 1998 Jun; 58(12):2652-60. PubMed ID: 9635593
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.
Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I
Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
